Carisma Therapeutics Inc. (CARM NASDAQ) stock market data APIs
$0.0535
-0(-0%)
as of December 5, 2025
Try our APIs with
free plan!
Carisma Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Prev. Close
0.0535
Open
0.0486
High
0.0602
Low
0.0454
52 wk Range
0.026-1.27
Market Cap
2 218 K
P/E Ratio
0.2789
Shares Outstanding
41 845 K
Revenue
52 632 K
EPS
-0.23
Beta
3.691
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Carisma Therapeutics Inc. data using free add-ons & libraries
Get Carisma Therapeutics Inc. Fundamental Data
Carisma Therapeutics Inc. Fundamental data includes:
- Net Revenue: 52 632 K
- EBITDA: 14 177 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Carisma Therapeutics Inc. News
New
CARMILA: Information Concerning the Total Number of Voting Rights and Share
Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement généralde l’Autorité des marchés financiers (General regulation of t...
Carmila (ENXTPA:CARM): Evaluating Valuation Opportunities After Recent Modest Share Price Moves
Carmila (ENXTPA:CARM) has drawn some attention recently, with its share price making modest moves over the past week and month. Investors seem to be weighing its latest performance patterns after a pe...
Carmila Sells €37.3m of Non-Strategic Assets in Spain and Exceeds Its 2025 Disposal Target
PARIS, November 17, 2025--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM) is continuing the optimisation of its capital with the disposal of four assets in Spain. The transaction, which amount...
Carmila: Information Concerning the Total Number of Voting Rights and Share
Provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement généralde l’Autorité des marchés financiers (General regulation of t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
